This page is available in multiple languages
Select Language

Pharming Group sounds gong to mark a summer of strategic progress


Sijmen de Vries, CEO of Pharming Group, Jaap Blaak, Chairman of the Board of Supervisory Directors of Pharming Group and the Pharming management team, visit Euronext Amsterdam to sound the gong and open trading.

The gong ceremony marks a summer of significant strategic progress for Pharming. Last week, Pharming and its US partner, Salix, announced the initiation of a randomized double blind placebo-controlled, crossover, Phase II clinical study of RUCONEST. Earlier in August Pharming announced the acquisition of certain assets of Transgenic Rabbit Models SASU (TRM), a private French company in liquidation; for € 0.5 million in cash. Through the acquisition Pharming gained access to five potential new product leads. In addition, Pharming gained access to transgenic rabbit founder technology and know-how developed by TRM. In July, Pharming announced that the Food and Drug Administration approved RUCONEST® in the USA. A US$20 million milestone payment from Salix will become payable upon the first commercial sale of Ruconest® in the US, representing significant non-dilutive funding to the company. Salix currently plans on making RUCONEST® available to patients during the fourth quarter of 2014. 

Sijmen de Vries, Pharming CEO, said: “We are delighted with the very significant regulatory and commercial progress we have made over the past summer, particularly the approval of RUCONEST® in the US, the initiation of the clinical study with RUCONEST®, and the acquisition of assets from TRM.

For more information:

Download photo